HAPPE Spine

Executive Summary

HAPPE Spine is a privately held medical device company headquartered in Austin, Texas, focused on advancing spinal fusion technology through its proprietary material science platform. The company’s flagship product, INTEGRATE®-C, is an interbody fusion cage that uniquely combines a porous PEEK structure with fully integrated hydroxyapatite throughout the implant. This design aims to enhance osseointegration and bone fusion outcomes compared to traditional PEEK or titanium cages. Spinal fusion is a large and growing market driven by an aging population and increasing prevalence of degenerative spine conditions. HAPPE Spine differentiates itself by offering a material that mimics the mechanical properties of bone while promoting biological attachment. With its innovative approach, HAPPE Spine is well-positioned to capture market share in the competitive spinal implant space. The INTEGRATE®-C has received initial regulatory clearances, and the company is expanding clinical evidence to support broader indications. Key upcoming catalysts include potential FDA clearance for multi-level fusion applications, publication of longer-term clinical data, and strategic distribution partnerships. While the company faces competition from established players like Medtronic and Johnson & Johnson, its unique material platform provides a distinct value proposition. If clinical outcomes continue to be positive, HAPPE Spine could become an attractive acquisition target or scale independently.

Upcoming Catalysts (preview)

• Q3 2026FDA 510(k) Clearance for INTEGRATE®-C in Multi-Level Fusion70% success
• Q4 2026Publication of 2-Year Clinical Outcomes80% success
• Q2 2026New Distribution Partnership for US Market60% success